These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 4064046)

  • 21. [Usefulness of AgNOR technique in the interpretation of serous effusions].
    Rocher AE; Blanco AM; Palaoro LA
    Rev Med Chil; 2000 Sep; 128(9):963-8. PubMed ID: 11349500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytologic diagnosis of malignant mesothelioma in serous effusions using an antimesothelial-cell antibody.
    Donna A; Betta PG; Bellingeri D; Tallarida F; Pavesi M; Pastormerlo M
    Diagn Cytopathol; 1992; 8(4):361-5. PubMed ID: 1638937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calretinin. A selective marker of normal and neoplastic mesothelial cells in serous effusions.
    Barberis MC; Faleri M; Veronese S; Casadio C; Viale G
    Acta Cytol; 1997; 41(6):1757-61. PubMed ID: 9390137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The expression pattern of beta-catenin in mesothelial proliferative lesions and its diagnostic utilities.
    Dai Y; Bedrossian CW; Michael CW
    Diagn Cytopathol; 2005 Nov; 33(5):320-4. PubMed ID: 16240396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemical localization of prekeratin filaments in benign and malignant cells in effusions. Comparison with intermediate filament distribution by electron microscopy.
    Kahn HJ; Hanna W; Yeger H; Baumal R
    Am J Pathol; 1982 Nov; 109(2):206-14. PubMed ID: 6182803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Contribution of immunocytochemical marking of benign cells to the diagnosis of serous effusions].
    Gaulier A; Cava E; Chosia MC; Pore G; Marsan C
    Ann Pathol; 1986; 6(4-5):323-8. PubMed ID: 3814272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An unusual cytologic presentation of mesothelioma in serous effusions.
    Spriggs AI; Grunze H
    Acta Cytol; 1983; 27(3):288-92. PubMed ID: 6575546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cytologic diagnosis of mesothelioma.
    Ehya H
    Semin Diagn Pathol; 1986 Aug; 3(3):196-203. PubMed ID: 3616223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions.
    Facchetti F; Lonardi S; Gentili F; Bercich L; Falchetti M; Tardanico R; Baronchelli C; Lucini L; Santin A; Murer B
    Virchows Arch; 2007 Sep; 451(3):669-80. PubMed ID: 17609977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 9p21 Deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis.
    Onofre FB; Onofre AS; Pomjanski N; Buckstegge B; Grote HJ; Böcking A
    Cancer; 2008 Jun; 114(3):204-15. PubMed ID: 18306350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Malignant effusions: from diagnosis to biology.
    Davidson B
    Diagn Cytopathol; 2004 Oct; 31(4):246-54. PubMed ID: 15452897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunocytochemical staining of serous effusions with the monoclonal antibody Ber-EP4.
    De Angelis M; Buley ID; Heryet A; Gray W
    Cytopathology; 1992; 3(2):111-7. PubMed ID: 1617160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.
    Davidson B; Berner A; Nesland JM; Risberg B; Kristensen GB; Tropé CG; Bryne M
    Hum Pathol; 2000 Sep; 31(9):1081-7. PubMed ID: 11014575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of three cytologic preparation methods and immunocytochemistries to distinguish adenocarcinoma cells from reactive mesothelial cells in serous effusion.
    Ueda J; Iwata T; Ono M; Takahashi M
    Diagn Cytopathol; 2006 Jan; 34(1):6-10. PubMed ID: 16355377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytologic diagnosis of metastatic sarcoma in effusions.
    Longatto-Filho A; Bisi H; Bortolan J; Granja NV; Lombardo V
    Acta Cytol; 2003; 47(2):317-8. PubMed ID: 12685210
    [No Abstract]   [Full Text] [Related]  

  • 36. Platelet-derived growth factor receptor immunoreactivity in mesothelioma and nonneoplastic mesothelial cells in serous effusions.
    Ascoli V; Scalzo CC; Facciolo F; Nardi F
    Acta Cytol; 1995; 39(4):613-22. PubMed ID: 7543232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Qualitative distinctive differences between the vacuoles of mesothelioma cells and of cells from metastatic carcinoma exfoliated in pleural fluid.
    Boon ME; Veldhuizen RW; Ruinaard C; Snieders MW; Kwee WS
    Acta Cytol; 1984; 28(4):443-9. PubMed ID: 6589924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative analysis of integrin expression in effusions using flow cytometric immunophenotyping.
    Sigstad E; Dong HP; Nielsen S; Berner A; Davidson B; Risberg B
    Diagn Cytopathol; 2005 Nov; 33(5):325-31. PubMed ID: 16240402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utility of CD138 (syndecan-1) in distinguishing carcinomas from mesotheliomas.
    Saqi A; Yun SS; Yu GH; Alexis D; Taub RN; Powell CA; Borczuk AC
    Diagn Cytopathol; 2005 Aug; 33(2):65-70. PubMed ID: 16007640
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distinction between cells in serous effusions using a panel of antibodies.
    Lauritzen AF
    Virchows Arch A Pathol Anat Histopathol; 1987; 411(3):299-304. PubMed ID: 2441518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.